Evotec Se Adr Stock Fundamentals
| EVO Stock | USD 4.89 0.40 8.91% |
Evotec SE ADR fundamentals help investors to digest information that contributes to Evotec SE's financial success or failures. It also enables traders to predict the movement of Evotec Stock. The fundamental analysis module provides a way to measure Evotec SE's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evotec SE stock.
At this time, Evotec SE's Research Development is very stable compared to the past year. As of the 25th of November 2024, Cost Of Revenue is likely to grow to about 636.7 M, though Operating Income is likely to grow to (101.7 M). Evotec | Select Account or Indicator |
Evotec SE ADR Company Operating Margin Analysis
Evotec SE's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Evotec SE Operating Margin | (0.18) % |
Most of Evotec SE's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evotec SE ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Evotec Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Evotec SE ADR has an Operating Margin of -0.1768%. This is 99.5% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The operating margin for all United States stocks is 96.79% lower than that of the firm.
Evotec SE ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Evotec SE's current stock value. Our valuation model uses many indicators to compare Evotec SE value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evotec SE competition to find correlations between indicators driving Evotec SE's intrinsic value. More Info.Evotec SE ADR is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At this time, Evotec SE's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Evotec SE's earnings, one of the primary drivers of an investment's value.Evotec Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evotec SE's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evotec SE could also be used in its relative valuation, which is a method of valuing Evotec SE by comparing valuation metrics of similar companies.Evotec SE is currently under evaluation in operating margin category among its peers.
Evotec SE Current Valuation Drivers
We derive many important indicators used in calculating different scores of Evotec SE from analyzing Evotec SE's financial statements. These drivers represent accounts that assess Evotec SE's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evotec SE's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.7B | 3.5B | 4.7B | 2.7B | 3.8B | 4.0B | |
| Enterprise Value | 2.7B | 3.6B | 4.7B | 2.8B | 3.9B | 4.1B |
Evotec SE ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evotec SE's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evotec SE's managers, analysts, and investors.Environmental | Governance | Social |
Evotec Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0177 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 1.68 B | ||||
| Shares Outstanding | 355.11 M | ||||
| Shares Owned By Institutions | 2.19 % | ||||
| Number Of Shares Shorted | 220.13 K | ||||
| Price To Earning | 444.00 X | ||||
| Price To Book | 1.57 X | ||||
| Price To Sales | 2.43 X | ||||
| Revenue | 781.43 M | ||||
| Gross Profit | 151.54 M | ||||
| EBITDA | (7.16 M) | ||||
| Net Income | (83.91 M) | ||||
| Cash And Equivalents | 823.67 M | ||||
| Cash Per Share | 2.33 X | ||||
| Total Debt | 626.2 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 5.46 X | ||||
| Cash Flow From Operations | 33.95 M | ||||
| Short Ratio | 2.32 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Price To Earnings To Growth | 3.15 X | ||||
| Target Price | 6.2 | ||||
| Number Of Employees | 5.01 K | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 1.7 B | ||||
| Total Asset | 2.3 B | ||||
| Retained Earnings | (476.29 M) | ||||
| Working Capital | 438.59 M | ||||
| Five Year Return | 4.88 % | ||||
| Net Asset | 2.3 B |
About Evotec SE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evotec SE ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evotec SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evotec SE ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 107.9 M | 113.2 M | |
| Total Revenue | 781.4 M | 820.5 M | |
| Cost Of Revenue | 606.4 M | 636.7 M | |
| Stock Based Compensation To Revenue | 0.01 | 0.02 | |
| Sales General And Administrative To Revenue | 0.20 | 0.26 | |
| Research And Ddevelopement To Revenue | 0.07 | 0.07 | |
| Capex To Revenue | 0.28 | 0.29 | |
| Revenue Per Share | 4.42 | 4.64 | |
| Ebit Per Revenue | (0.06) | (0.06) |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving against Evotec Stock
| 0.9 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.84 | TCHH | Trustcash Holdings | PairCorr |
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.75 | AGL | agilon health Buyout Trend | PairCorr |
| 0.74 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Evotec SE Piotroski F Score and Evotec SE Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.